Madrigal Pharmaceuticals, Inc. (MDGL) News
Filter MDGL News Items
MDGL News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MDGL News Highlights
- For MDGL, its 30 day story count is now at 9.
- Over the past 25 days, the trend for MDGL's stories per day has been choppy and unclear. It has oscillated between 1 and 6.
- FAT, MG and DRUG are the most mentioned tickers in articles about MDGL.
Latest MDGL News From Around the Web
Below are the latest news stories about Madrigal Pharmaceuticals Inc that investors may wish to consider to help them evaluate MDGL as an investment opportunity.
Madrigal Pharmaceuticals Q4 net loss widens Y/YMadrigal Pharmaceuticals (NASDAQ:MDGL) Q4 net loss increased to -$64.55M, compared to -$59.12M in Q4 2020. Q4 net interest income was $52K, compared to $432K in the prior year period. The company said the decreases in interest income for Q4 and FY 2021 was mainly due to lower average principal balances in... |
Madrigal Pharmaceuticals Provides Business and Clinical Updates and Reports 2021 Fourth Quarter and Full Year Financial ResultsCONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for non-alcoholic steatohepatitis (NASH), today provides a summary of corporate accomplishments and reports its fourth quarter and full year 2021 financial results. Paul Friedman, M.D., Chief Executive Officer of Madrigal, stated, “2021 was a year of significant progress for Madrigal as we continued to advance our industry-leadi |
VKTX, FRSX and SEAC among pre market gainersMadrigal Pharmaceuticals MDGL +15% liver disease candidate improved key patient outcomes in late-stage study.Yoshitsu Co (TKLF) +14% |
Why Madrigal Pharmaceuticals Stock Briefly Spiked TodayShares of clinical-stage biotech Madrigal Pharmaceuticals (NASDAQ: MDGL) rose by as much as 18% in pre-market action Monday morning. The gains came in response to a positive top-line readout from a phase 3 clinical trial for resmetirom, its experimental fatty liver disease drug candidate. Madrigal said that the drug was safe and well-tolerated at both the 80 mg and 100 mg dose levels assessed in the trial. |
Madrigal shares rise, market cap surpasses $1B on positive late-stage study results for lead drug candidateFounded in 2011, the Conshohocken company has grown to about 50 employees and is led by the husband-and-wife team. |
Madrigal Pharma's Kidney Disease Candidate Improves Liver, Cardiovascular HealthMadrigal Pharmaceuticals Inc (NASDAQ: MDGL) has announced topline data from Phase 3 MAESTRO-NAFLD-1 safety study of resmetirom. The 52-week study demonstrated that resmetirom was safe and well-tolerated at 80 and 100 mg once a day dosing. Additionally, resmetirom helped patients with presumed non-alcoholic steatohepatitis (NASH) achieve significant, clinically relevant reductions in liver fat and atherogenic lipids. A total of 972 patients were randomized in the double-blind arms of the MAESTRO- |
UPDATE 1- Madrigal's drug candidate reduces fatty liver in late-stage NASH trialMadrigal Pharmaceuticals Inc said on Monday a late-stage trial showed that its experimental drug helped reduce liver fat and certain lipids in patients with non-alcoholic steatohepatitis (NASH), an inflammatory disease of the liver. "These positive results ... support our conviction that resmetirom has the potential to be the first medication approved for the treatment of patients with NASH and liver fibrosis," Chief Executive Officer Paul Friedman said. NASH is a chronic liver disease characterized by excess fat, inflammation and cell damage in liver that can cause fibrosis or scarring of the organ, ultimately leading to cirrhosis or liver cancer. |
Positive Topline Phase 3 MAESTRO-NAFLD-1 Data Demonstrate Resmetirom was Safe, Well-Tolerated and Provided Statistically Significant Improvements in Key Measures of Liver and Cardiovascular HealthPrimary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was safe and well-tolerated at 80 and 100 mg in patients treated for 52 weeksProvided significant and clinically relevant reductions in liver fat as measured by magnetic resonance imaging proton density fat-fraction (MRI-PDFF)Significantly reduced atherogenic lipids, including LDLc, apolipoprotein B and triglycerides The increased en |
Madrigal Pharmaceuticals To Announce Topline Results from the Phase 3 MAESTRO-NAFLD-1 Study of Resmetirom on Monday, January 31stCONSHOHOCKEN, Pa., Jan. 30, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, plans to announce topline results from the Phase 3 MAESTRO-NAFLD-1 study of resmetirom on Monday, January 31st, 2022. The schedule for the press release and conference call/webcast is as follows: • MAESTRO-NAFLD-1 Press Release: January 31st, 2022 at 7:00 am EST• MAESTRO-NAFLD-1 Conference Call: Januar |
Dominic F. Labriola Joins Madrigal Pharmaceuticals as Chief Data and Analytics OfficerCONSHOHOCKEN, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company pursuing novel therapeutics for fatty liver diseases, announced today that Dr. Dominic F. Labriola has joined Madrigal as Senior Vice President and Chief Data and Analytics Officer. “We are pleased to welcome Dr. Labriola to Madrigal at this pivotal time for the company,” said Becky Taub, M.D., President R&D and CMO of Madrigal. “With 35 years of experienc |